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BACKGROUND: The etiology of frontotemporal dementia (FTD) is poorly understood. To identify genes with pre-
dicted expression levels associated with FTD, we integrated summary statistics with external reference gene
expression data using a transcriptome-wide association study approach.
METHODS: FUSION software was used to leverage FTD summary statistics (all FTD: n = 2154 cases, n = 4308
controls; behavioral variant FTD: n = 1337 cases, n = 2754 controls; semantic dementia: n = 308 cases, n = 616
controls; progressive nonfluent aphasia: n = 269 cases, n = 538 controls; FTD with motor neuron disease: n = 200
cases, n = 400 controls) from the International FTD-Genomics Consortium with 53 expression quantitative loci tissue
type panels (n = 12,205; 5 consortia). Significance was assessed using a 5% false discovery rate threshold.
RESULTS: We identified 73 significant gene–tissue associations for FTD, representing 44 unique genes in 34 tissue
types. Most significant findings were derived from dorsolateral prefrontal cortex splicing data (n = 19 genes, 26%).
The 17q21.31 inversion locus contained 23 significant associations, representing 6 unique genes. Other top hits
included SEC22B (a gene involved in vesicle trafficking), TRGV5, and ZNF302. A single gene finding (RAB38) was
observed for behavioral variant FTD. For other clinical subtypes, no significant associations were observed.
CONCLUSIONS: We identified novel candidate genes (e.g., SEC22B) and previously reported risk regions (e.g.,
17q21.31) for FTD. Most significant associations were observed in dorsolateral prefrontal cortex splicing data despite
the modest sample size of this reference panel. This suggests that our findings are specific to FTD and are likely to be
biologically relevant highlights of genes at different FTD risk loci that are contributing to the disease pathology.
https://doi.org/10.1016/j.biopsych.2020.12.023Frontotemporal dementia (FTD) is a heterogeneous neurode-
generative disorder characterized by frontal and/or temporal
patterns of atrophy. Clinically, patients with FTD present with
the behavioral variant of FTD (bvFTD) or language variants
such as semantic dementia (SD) and progressive nonfluent
aphasia (PNFA) (1). In 10% of all cases, FTD co-occurs with
motor neuron diseases (FTD-MND) (2).
Where FTD is mostly sporadic (80%), approximately 20% of
all FTD cases are familial, with the most common Mendelian
mutations including the hexanucleotide repeat expansion at
the C9ORF72 locus on chromosome 9 and mutations in
microtubule-associated protein tau (MAPT) and progranulin
(GRN) genes in and near the chromosome 17q21 inversion
locus (3–7). Genome-wide association studies (GWASs) in FTD
have also identified genetic risk variants, each having small
associations with disease risk (8–11). The number of known
FTD disease susceptibility loci remains small owing to limited
power for discovery in the relatively small sample sizes of the
GWASs so far with ncases , 5000. At this time, it is poorlySEE COMMENTARY
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etiology, while such knowledge is essential for understanding
disease pathology and the development of therapeutic
interventions.
Genetic risk variants identified in GWASs are often located
in noncoding regions with and without regulatory motifs
outside the protein encoding sequences (12). These risk vari-
ants are likely to predispose individuals to disease suscepti-
bility by modulating messenger RNA expression levels through
local (cis) or distal (trans) expression quantitative trait loci
(eQTL) (13). The FTD risk variant rs302652 nearby RAB38 is a
local eQTL, decreasing RAB38 gene expression in monocytes
(11) and potentially influencing bvFTD disease risk by modu-
lating RAB38 gene expression levels in specific brain areas.
However, the joint effects of genetic risk loci for FTD on (dif-
ferential) gene expression across multiple tissue types are
unclear.
Transcriptome-wide association studies (TWASs) have
emerged as a way to identify associations between traits andON PAGE e37
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PrediXcan, summary data–based Mendelian randomization,
and FUSION (14-16). TWAS leverage the combined effects of
multiple single nucleotide polymorphisms (SNPs), on either the
individual level (PrediXcan and summary data–based Mende-
lian randomization) or the summary level (s-PrediXcan and
FUSION), on gene expression, thereby increasing power to find
novel associations over a traditional GWAS when gene
expression mediates risk (14–16). Imputation of the genetic
control of gene expression is now widely used to decipher how
GWAS-identified alleles may contribute to disease risk, and to
identify specific candidate genes through which this effect is
regulated. In this study, we performed a multitissue TWAS on
sporadic FTD and its clinical subtypes to identify genes whose
changes in expression play a role in FTD and to identify tissue
types relevant to FTD. As a secondary aim of the study, we
performed a TWAS-based enrichment analysis and explored
whether FTD shows overlap in differential expression with
neuropsychiatric disorders that show clinical overlap with FTD.
METHODS AND MATERIALS
GWAS Summary Statistics
GWAS summary statistics from the International-FDG Con-
sortium (IFGC) (https://ifgcsite.wordpress.com) on FTD (n =
2154 cases, n = 4308 controls) and the FTD clinical subtypes
bvFTD (n = 1377 cases, n = 2754 controls), SD (n = 308 cases,
n = 616 controls), PNFA (n = 269 cases, n = 538 controls), and
FTD-MND (n = 200 cases, n = 400 controls) were used
(Table S1 in Supplement 2). Written informed consent was
obtained from all participants according to the Declaration of
Helsinki. For all study sites, the study was approved by the
medical ethics committee.
Preprocessing and quality check procedures have been
described previously (11). SNPs were converted from chr:bp to
rsID coordinates using Phase 3 1000 Genomes Project data
(17). Summary statistics were quality checked and converted
to LD-score format using the munge_stats.py utility from
LDSC, leaving 1,068,995 SNPs for final analysis for all phe-
notypes (18) (see Supplemental Methods in Supplement 1).
eQTL Reference Panels
Local (cis) eQTL datasets from 5 different cohorts (n = 12,205)
on 53 tissue types were downloaded from the FUSION website
(http://gusevlab.org/projects/fusion) (Table 1). The 5 cohorts
included the CommonMind Consortium (CMC) (n = 452) (19),
the Netherlands Twin Registry (NTR) (n = 1247) (20), the Car-
diovascular Risk in Young Finns Study (YFS) (n = 1264) (21),
the Metabolic Syndrome in Men Study (METSIM) (n = 562) (22),
and the Genotype Tissue Expression Project (GTEx) version 7
(https://gtexportal.org/home/datasets) (n = 752). Local eQTLs
were calculated by leveraging gene expression with genetic
variation data (i.e., SNPs within 61 Mb of the transcriptional
start site of the gene). More detailed information on genotyping
and gene expression analyses for these datasets have been
described previously: CMC (23), NTR, YFS, METSIM (15), and
GTEx (24).
Local eQTL datasets from tissue types less relevant to FTD
(e.g., blood) were included in this study because local eQTLs826 Biological Psychiatry April 15, 2021; 89:825–835 www.sobp.org/joare highly conserved across tissues (25) and eQTL datasets
with nonbrain tissues consist of substantially larger sample
sizes, thereby maximizing power to detect significant associ-
ations between local gene expression and FTD GWAS SNPs.Functional Mapping and Annotation
To examine the proportion of noncoding variants among FTD-
risk SNPs, we annotated SNPs from the IFGC GWAS on FTD
using Functional Mapping and Annotation (FUMA) (https://
fuma.ctglab.nl) (26). The most significant (p , 5 3 1026)
SNPs and SNPs in linkage disequilibrium (LD) (r2 $ .6) with
these were used for further inspection using 1000 Genomes
Project data (17). Lead SNPs were defined as being indepen-
dent from each other at r2 . .1. LD blocks of independent
SNPs were merged into a genomic locus if they were closely
located to each other (i.e., ,250 kb).
Lead and correlated SNPs were annotated for potential
regulatory functions (RegulomeDB) (27), 15-core chromatin
state predicted by ChromHMM (28), functional consequences
on gene functions annotated by ANNOVAR (29), and deleteri-
ousness score (Combined Annotation Dependent Depletion)
(30). To test for enrichment of functional consequences of lead
and correlated SNPs (as estimated with ANNOVAR), we per-
formed a Fisher’s exact test using a 5% false discovery rate
(FDR) significance threshold (see https://fuma.ctglab.nl/
tutorial#annov). The enrichment value was calculated as the
proportion of SNPs with an annotation divided by the pro-
portion of SNPs with an annotation relative to all available
SNPs in Phase 3 1000 Genomes Project data (17).Statistical Analysis
TWAS Analysis. To identify genes whose local-regulated
expression is associated with FTD and its clinical subtypes
(i.e., bvFTD, SD, PNFA, and FTD-MND), we performed TWAS
analyses using FUSION software (http://gusevlab.org/projects/
fusion) with default settings (15). FUSION estimates the ge-
netic correlation between local gene expression and FTD by
integrating GWAS summary statistics with external gene
expression reference panel data while accounting for LD
structure among SNPs [using Phase 3 1000 Genomes Project
data (17)]. To account for LD structure, we used 1000 Ge-
nomes (all ancestries) data as LD reference panel.
To study whether GWAS SNPs colocalized with eQTLs, we
performed a Bayesian colocalization analysis for all associa-
tions with pTWAS uncorrected , .05 using the COLOC package in
R (https://cran.r-project.org/web/packages/coloc) (31) imple-
mented in FUSION. A joint analysis was performed to identify
which genes are conditionally independent.
TWAS results are presented including the major histocom-
patibility (MHC) locus because the FTD GWAS included
genome-wide significant loci within the MHC region (11). Re-
sults on gene–tissue associations per phenotype (i.e., FTD,
bvFTD, SD, PNFA, and FTD-MND) were corrected for multiple
comparisons using a 5% FDR significance threshold. Signifi-
cant TWAS loci were identified as novel if the strongest FTD-
associated SNP was not nominally significant (p . .05) in the
IFGC GWAS (11) within 61 Mb of the transcriptional start site
of the gene’s region.urnal
Table 1. Descriptive Statistics for Tissue Reference Panels and TWAS Results





CMC Brain: Dorsolateral prefrontal
cortex
452 5244 5 0
CMC Brain: Dorsolateral prefrontal
cortex (splicing)
452 7514 (3221) 19 (13 unique) 0
GTEx Adipose: Subcutaneous 385 7669 (7668) 1 1
GTEx Adipose: Visceral (omentum) 313 5765 (5763) 1 0
GTEx Adrenal gland 175 4252 (4251) 2 0
GTEx Artery: Aorta 267 6040 1 0
GTEx Artery: Coronary 152 3026 2 0
GTEx Artery: Tibial 388 7732 (7730) 2 0
GTEx Brain: Amygdala 88 1710 0 0
GTEx Brain: Anterior cingulate cortex
(BA24)
109 2523 1 0
GTEx Brain: Caudate (basal ganglia) 144 3418 0 0
GTEx Brain: Cerebellar hemisphere 125 4131 (4130) 2 0
GTEx Brain: Cerebellum 154 5513 0 0
GTEx Brain: Cortex 136 3761 0 0
GTEx Brain: Frontal cortex (BA9) 118 2934 1 0
GTEx Brain: Hippocampus 111 2129 0 0
GTEx Brain: Hypothalamus 108 2147 1 0
GTEx Brain: Nucleus accumbens
(basal ganglia)
130 3032 0 0
GTEx Brain: Putamen (basal ganglia) 111 2638 0 0
GTEx Brain: Spinal cord (cervical C1) 83 1892 1 0
GTEx Brain: Substantia nigra 80 1505 0 0
GTEx Breast: Mammary tissue 251 4701 (4700) 1 0
GTEx Blood: EBV-transformed
lymphocytes
117 2558 (2557) 0 0
GTEx Transformed fibroblasts 300 6957 (6956) 1 1
GTEx Colon: Sigmoid 203 4559 (4558) 1 1
GTEx Colon: Transverse 246 4935 (4934) 1 1
GTEx Esophagus: Gastroesophageal
junction
213 4563 (4562) 1 1
GTEx Esophagus: Mucosa 358 7551 (7549) 1 0
GTEx Esophagus: Muscularis 335 7287 (7286) 2 1
GTEx Heart: Atrial appendage 264 5316 1 0
GTEx Heart: Left ventricle 272 4750 1 0
GTEx Liver 153 2711 0 1
GTEx Lung 383 7270 (7268) 2 0
GTEx Minor salivary gland 85 1681 0 0
GTEx Muscle: Skeletal 491 6990 (6989) 3 0
GTEx Nerve: Tibial 361 9064 (9062) 2 0
GTEx Ovary 122 2620 (2619) 0 1
GTEx Pancreas 220 4768 (4767) 2 0
GTEx Pituitary 157 4122 (4121) 2 0
GTEx Prostate 132 2600 1 0
GTEx Skin: Not sun exposed
(suprapubic)
335 6984 (6983) 1 0
GTEx Skin: Sun exposed (lower leg) 414 8343 (8342) 2 0
GTEx Small intestine: Terminal ileum 122 2664 0 0
GTEx Spleen 146 4161 0 0
GTEx Stomach 237 4145 (4143) 0 0
GTEx Testis 225 8685 (8682) 1 0
GTEx Thyroid 399 9229 (9225) 2 0
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GTEx Uterus 101 1972 0 0
GTEx Vagina 106 1852 0 0
GTEx Whole blood 369 1898 2 0
METSIM Adipose 563 4458 4 0
NTR Peripheral blood 1247 2356 0 0
YFS Whole blood 1264 5568 (5567) 0 0
Total – – 246,320 (241,893 non-MHC,
233,420 unique)
73 (67 unique) 8
No significant gene–tissue interactions were observed for semantic dementia, progressive nonfluent aphasia, and FTD with motor neuron
diseases.
BA, Brodmann area; CMC, CommonMind Consortium; EBV, Epstein–Barr virus; FTD, frontotemporal dementia; GTEx, Genotype Tissue
Expression Project; METSIM, Metabolic Syndrome in Men Study; NTR, Netherlands Twin Registry; TWAS, transcriptome-wide association study;
YFS, Cardiovascular Risk in Young Finns Study.
aNumber of subjects included in reference panel study.
bNumber of genes that could be estimated. Numbers in parentheses depict the number of unique genes that could be estimated.
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estimate the proportion of disease heritability mediated by
local gene expression, we performed a mediated expression
score regression (MESC) analysis per tissue type, excluding
SNPs located on the MHC locus (https://github.com/
douglasyao/mesc) (32). Here, we define h2med as heritability
mediated by local gene expression, h2g as disease heritability,
and h2med/h
2
g as the proportion of heritability mediated by
local gene expression. First, for each gene, local heritability
scores were estimated while accounting for LD structure.
Genes were partitioned into bins according to their local heri-
tability because this has been shown to provide unbiased
h2med/h
2





expression scores estimated in the previous step and GWAS
summary statistics on FTD. Because MESC produces biased
estimates for eQTL reference panels with small sample sizes,
only eQTL datasets with sample sizes .300 (n = 17) were
included.
Enrichment Analysis. Competitive enrichment analysis
on FTD TWAS results was performed using TWAS-based
gene set enrichment analysis (TWAS-GSEA) (https://github.
com/opain/TWAS-GSEA) (33). TWAS-GSEA is an adapted
method of GWAS-based enrichment analysis implemented
in MAGMA software (34). In brief, this method examines
whether TWAS results are enriched for specific pathways
while accounting for LD structure. Per phenotype, TWAS-
GSEA was performed simultaneously for all 53 eQTL
datasets. The file used as eQTL reference panel for the
TWAS-GSEA analysis included unique gene identifiers only;
if genes were present in multiple local eQTL datasets, the
gene with the best prediction of expression (as estimated by
cross-validated R2 [MODELCV.R2]) was used in the GSEA.
Gene identifiers in TWAS result files were converted to
Entrez ID format using the biomaRt package in R, resulting
in 15,004 (14,813 non-MHC) unique Entrez IDs for FTD and
all clinical FTD subtypes. TWAS results were tested for
enrichment across 6778 Gene Ontology biological process
gene sets. Per phenotype, results were corrected for the
number of gene sets using a 5% FDR significance threshold.828 Biological Psychiatry April 15, 2021; 89:825–835 www.sobp.org/joData Availability. The GWAS summary statistics on FTD
can be acquired via the IFGC (https://ifgcsite.wordpress.com/
data-access). Local eQTL reference weights can be down-
loaded from the FUSION website (http://gusevlab.org/projects/
fusion).
RESULTS
Most Risk Variants for FTD Are Located in
Noncoding Regions
For FTD, FUMA annotated 3103 SNPs from 13 independent
lead SNPs located in 10 genomic risk loci. These SNPs
showed enrichment for intronic (50.2%, penrichment = 2.98 3
102120), intronic noncoding RNA (24.3%, penrichment = 3.15 3
102124), intergenic (19.3%, penrichment = 0), and 50UTR (0.75%,
penrichment = 1.61 3 10
26) regions, whereas only 1.4% of all
SNPs were located in exonic regions (penrichment = .32)
(Table S2 in Supplement 2). Most SNPs (93.1%) were
located in open chromatin regions (range of minimum chro-
matin state across 127 tissue/cell types = 1–7), and 11.4%
of the annotated SNPs had potential regulatory elements, as
indicated by a RegulomeDB score below 2 (Figure S1 in
Supplement 1).
Predicted Gene Expression Levels Show 73
Associations With FTD
Predicted gene expression levels in 53 tissue types (range
of genes per tissue type = 1505–9229) were tested for
association with FTD. We identified 73 significant gene–
tissue associations for FTD, representing 44 (40 non-
MHC) unique genes in 34 tissue types (Table 1, Table S3
in Supplement 2, Figure 1, and Figure 2). In total, 39.7%
(29/73) of these transcriptome-wide significant associa-
tions had supporting evidence from colocalization ana-
lyses (Table S4 in Supplement 2). The strongest genic
FTD TWAS associations included ARL17B on chromo-
some 17 (brain cerebellar hemisphere pFDR = 9.02 3
10222), ZNF302 on chromosome 19 (dorsolateral pre-
frontal cortex [DLPFC] splicing data pFDR = 5.80 3 10
28),
LRRC37A (lung pFDR = 1.58 3 10
25), SEC22B onurnal
Figure 1. Miami plot on FTD TWAS (top) and GWAS (bottom). In total, 44 unique genes were associated with FTD across 34 tissue types. Each point depicts
a distinct gene–tissue association. TWAS hits with supporting evidence from colocalization analysis are highlighted in blue. The red line depicts the signifi-
cance threshold; pFDR , .05 for TWAS and p , 5 3 10
28 for GWAS. FDR, false discovery rate; FTD, frontotemporal dementia; GWAS, genome-wide as-
sociation study; TWAS, transcriptome-wide association study.
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23), and TRGV5P
on chromosome 17 (cells transformed fibroblasts pFDR =
2.39 3 1023) (Table 2). Of all transcriptome-wide signifi-
cant genes with supporting colocalization evidence, only
the association of SEC22B with FTD was novel, showing
no evidence for association in the FTD GWAS (minimal p
within 61 Mb of the gene’s region = 6.14 3 1022) (11)
(Table S5 in Supplement 2).
One region of interest is 17q21.31 on chromosome 17,
which contained 23 significant associations, representing 6
unique genes (i.e., ARL17B, KANSL1-AS1, LRRC37A,
MAPT, MAPT-AS1, and NSFP1). This locus is an inversion
polymorphism that has been associated previously with
neurodegenerative tauopathies but also with psychiatric
disorders such as autism spectrum disorder (33,35). Gene
expressions of most gene–tissue pairs were highly corre-
lated except for KANSL1-AS1, MAPT, and MAPT-AS1
(Figure S2 in Supplement 1). For the majority of significant
associations in 17q21.31 (n = 16, 69.6%), colocalization
analysis provided evidence for a shared causal genetic
variant between gene expression and FTD (Table S4 in
Supplement 2).
Another region was 7p14.1, for which predicted gene
expression of TRGV5 and its pseudogene TRGV5P achieved
transcriptome-wide significance in 4 different tissue types.
Colocalization analyses suggested that FTD and 7p14.1 gene
expression share a single causal association (Table S4 in
Supplement 2).BiologicalMost TWAS Associations Were Detected in DLPFC
Splicing Data
The brain-derived reference panels contributed the most to
the significant associations between gene expression and
FTD (43.8%, 32 gene–tissue associations), with the majority
derived from DLPFC splicing data (19 splicing variants, 13
unique, all outside MHC). A previous study showed that a
larger sample size and increased number of measured
genes of the eQTL reference panel correlates to a higher
number of significant hits (36). Despite the modest sample
size (nsample = 452) and number of measured genes
(ngenes unique = 3221, ngenes total = 7514), DLPFC splicing
data accounted for 26% of all transcriptome-wide hits,
thereby exceeding the number of significant hits compared
with eQTL tissue types with larger sample sizes (e.g., 0%
for YFS whole blood, nsample = 1264) and more measured
genes (e.g., 3% for thyroid, ngenes, unique = 9225, ngenes total =
9229) (Figure S3 and Figure S4 in Supplement 1). Accordingly,
FTD TWAS results showed significant enrichment for
DLPFC splicing data (p = 7.31 3 1023) (Table S6 in
Supplement 2).
MESC analysis showed that a substantial proportion of
FTD heritability was mediated by the local component of
gene expression levels (mean h2med = 35 6 4.7%). The tibial
nerve had the highest heritability mediated by local gene
expression levels (mean h2med = 59.5 6 2.2%), potentially
reflecting a genetic component underlying the comorbidity
underlying FTD and motor neuron diseases. For DLPFCPsychiatry April 15, 2021; 89:825–835 www.sobp.org/journal 829
Figure 2. Heatmap of z scores of genes with at least one transcriptome-wide significant association with FTD. FTD transcriptome-wide associations
demonstrate tissue-shared and tissue-specific effects. The association of imputed gene expression of genes located on region 17q21.31 (depicted in light
blue) with FTD seems to be preserved across most reported tissue types, albeit not statically significant. On the other hand, none of the 13 unique (splicing)
variants in the DLPFC CMC data was significant in other datasets. Transcriptome-wide significant associations (pFDR , .05) are depicted with an asterisk.
Blank squares indicate that gene weights were not available in the reference panel. CMC, CommonMind Consortium; DLPFC, dorsolateral prefrontal cortex;
FDR, false discovery rate; FTD, frontotemporal dementia; GTEx, Genotype Tissue Expression Project; METSIM, Metabolic Syndrome in Men Study; NTR,
Netherlands Twin Registry; YFS, Cardiovascular Risk in Young Finns Study.
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the eQTL panel with the largest sample size (i.e., YFS whole
blood data) this was 12.6 6 7.4%. A full overview of local
mediated heritability is presented in Figure S5 in
Supplement 1 (see SNP heritability estimates in Table S1 in
Supplement 2).830 Biological Psychiatry April 15, 2021; 89:825–835 www.sobp.org/joPredicted Gene Expression Levels on Clinical
Subtypes Separately Show Association With bvFTD
Only
Predicted gene expression levels in 53 tissue types (range of
genes per tissue type = 1505–9229) were tested for associa-
tion with bvFTD, SD, PNFA, and FTD-MND. Gene expressionurnal
Table 2. Transcriptome-wide Significant Associations With Supporting Evidence From Colocalization Analysis
Location Min p (TWAS) Min p (GWAS)a Jointly Significant Marginally Significant
17.q21.31 1.83 3 10226 5.94 3 1025 ARL17B, LRRC37A, NSFP1 ARL17B, KANSL1-AS1, LRRC37A, NSFP1
13.q34 5.56 3 1027 2.30 3 1023 ATP11A
6.p21.33 1.00 3 1025 6.49 3 1024 C4A
3.q23 1.26 3 1026 3.07 3 1023 CLSTN2
2.q35 4.57 3 1026 9.48 3 1024 KRT8P30
10.q21.2 1.24 3 1025 2.69 3 1022 RHOBTB1
1.p12 3.61 3 1027 8.88 3 1022 SEC22B
9.q22.31 7.21 3 1026 6.14 3 1022 SUSD3
7.p14.1 3.89 3 1027 2.24 3 1022 TRGV5 TRGV5, TRGV5P
19.q13.11 3.06 3 10212 2.63 3 1022 ZNF302 ZNF302
19.q13.41 9.09 3 1026 6.04 3 1022 ZNF468
GWAS, genome-wide association study; TWAS, transcriptome-wide association study.
aMin p (GWAS) represents the p value for the top single nucleotide polymorphism association within 61 Mb of the transcriptional site of the
gene’s region.
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bvFTD risk in 8 of 25 tissue panels (colon sigmoid pFDR =
4.02 3 1024, range of significant gene–tissue associations
pFDR = 4.02 3 10
24 to 4.37 3 1022) (Figure 3, Figure S6 in
Supplement 1, and Table S7 in Supplement 2). Colocalization
supported model 4 with a range posterior probability 4 of 0.64
to 1.0 (range posterior probability 3 = 0.003–0.04) (Table S8 in
Supplement 2). The former GWAS on bvFTD showed nominal
evidence for the association of RAB38 with FTD (rs302668
odds ratio = 0.81 [95% confidence interval = 0.71–0.91];
pGWAS = 2.44 3 10
27) (11). For SD, PNFA, and FTD-MND, no
significant transcriptome-wide associations were observed
(Figures S7, S8, and S9 in Supplement 1 and Tables S9–S14 in
Supplement 2).Implicated Genes Highlight Involvement of Amino
Acid Transport in FTD Pathogenesis
Full competitive results for the enrichment analysis on FTD and
its clinical subtypes are presented in Tables S15 to S24 in
Supplement 2. TWAS results for FTD were significantly
enriched for sulfur amino acid transport (with MHC pFDR = .04,
without MHC pFDR = .03) (Figures S11 and S12 in Supplement
1). For all other gene sets and traits, no gene sets were sig-
nificant after FDR correction.No Genetic Correlations Were Observed Between
Gene Expression FTD and Alzheimer’s Disease,
Amyotrophic Lateral Sclerosis, and Primary
Psychiatric Disorders
Given the similarities between FTD and several neuropsychi-
atric disorders, we explored the genetic correlations between
the predicted gene expression for FTD and Alzheimer’s dis-
ease (AD), amyotrophic lateral sclerosis (ALS), schizophrenia,
autism spectrum disorder, and major depressive disorder us-
ing RHOGE (37) (see Supplemental Methods in Supplement 1).
No significant correlations were observed after FDR correction
(Tables S25 and S26 in Supplement 2 and Figure S13 in
Supplement 1).BiologicalDISCUSSION
In this study, we aimed to better understand the genetic eti-
ology of sporadic FTD by identifying genes whose expression
plays a role in FTD, using a TWAS approach with increased
power of detecting loci compared with a traditional GWAS. We
identified 73 significant gene–tissue associations for FTD,
representing 44 unique genes in 34 tissue types. The 17q21.31
inversion region was replicated as risk region for FTD. SEC22B
was identified as likely novel risk gene for FTD. Interestingly,
most associations were derived from splicing data of the
DLPFC, a brain region that is nearly universally involved in FTD,
thereby providing some biological validation to the multitissue
TWAS approach in FTD. Moreover, these findings highlight the
importance of splicing events for disease risk (38). Our results
indicate that a large proportion of FTD risk loci modulate gene
expression levels, and we highlight these genes as potential
candidates for functional follow-up studies.
The majority of FTD risk variants were located in noncoding
regions, demonstrating that these variants likely have regula-
tory functions. A total of 44 genes were identified as differen-
tially expressed in FTD. We replicated the 17q21.31 locus as
risk factor for FTD. This region contained 23 significant asso-
ciations from 6 different genes: ARL17B, KANSL1-AS1,
LRRC37A, NSFP1, MAPT-AS1, and MAPT. Mutations in the
latter gene, MAPT, are identified as one of the most common
Mendelian mutations implicated in familial FTD (6). The
17q21.31 region contains a common inversion polymorphism
and has been associated not only with several neurodegen-
erative disorders (e.g., progressive supranuclear palsy, corti-
cobasal degeneration, AD, FTD) but also with psychiatric
disorders such as autism spectrum disorder (33,35,39–42).
Previous research has shown that different haplotypes of the
17q21.31 inversion affect expression of 17q21.31 genes in
blood and different brain regions (43). Here, we highlight the
role of differential gene expression of 17q21.31 genes across
several tissue types in the pathogenesis of FTD.
Another implicated gene was SEC22B on chromosome 1,
which showed evidence for differential gene expression in FTD
without achieving genome-wide significance in the corre-
sponding FTD GWAS (p . .05 within 61 Mb of SEC22B).Psychiatry April 15, 2021; 89:825–835 www.sobp.org/journal 831
Figure 3. Regional association plot of RAB38 for behavioral variant frontotemporal dementia. The top panel shows all the genes in the locus. The
transcriptome-wide marginally significant associated genes are highlighted in blue, and those that are jointly significant (i.e., RAB38 in colon sigmoid) are
highlighted in green. The bottom panel shows a Manhattan plot of the genome-wide association study data before (gray) and after (blue) conditioning on the
green genes. This locus goes from being genome-wide significant to being nonsignificant after conditioning on the predicted expression of RAB38. chr,
chromosome.
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PsychiatrySEC22B codes for a protein that plays an important role in
vesicle trafficking between the Golgi apparatus and the
endoplasmic reticulum, autophagy, and membrane fusion. The
latter is essential for the development of the nervous system,
including axonal and dendritic growth (44). Little is known
about the precise role of SEC22B in neurodegeneration, but
differential expression of this gene in the brain has been
associated with normal aging and AD (45,46).
We found increased C4A gene expression to be significantly
associated with FTD. The C4 gene has two functionally
different isoforms (i.e., C4A and C4B, both of which can vary in
structure and copy number) and is located on the MHC locus,
a locus strongly associated with immune-related processes.
Structural variation in C4A/B has been associated with
schizophrenia, probably affecting synaptic pruning (47,48). The
potential role of C4 (structure) in the etiology of FTD is not fully
understood yet. Human postmortem and mice model studies
on FTD demonstrate an association between upregulated C4A
gene expression and aggregation of transactive response
DNA-binding protein 43 (TDP), one of the most common
pathological subtypes underlying FTD (49,50). Although this
would suggest a specific relationship between upregulated
C4A gene expression and FTD pathology, increased C4A
gene expression has also been observed in AD and
schizophrenia (51).
We explored the genetic correlation between predicted
gene expression for FTD and primary psychiatric disorders AD
and ALS. Although FTD and psychiatric disorders overlap with
respect to symptoms and affected neuroanatomical regions,
we found no indications for an overlapping expression profile
(52,53). We further did not observe a significant overlap of
predicted gene expression for FTD with both AD and ALS.
Although previous studies have reported a shared genetic ar-
chitecture between FTD and ALS (54), our results suggest that832 Biological Psychiatry April 15, 2021; 89:825–835 www.sobp.org/jothe known clinical association between FTD and ALS (in
w10% of all cases) might not be driven by an overlap in gene
expression. Altogether, this suggests that at least part of the
FTD TWAS signal is specific for FTD rather than generic to
neuropsychiatric disorders.
Proteins differentially expressed in FTD showed enrichment
for the transport of sulfur amino acids (e.g., methionine,
cysteine), a process essential for the synthesis of antioxidants.
For example, transport of L-cystine (i.e., oxidized form of
cysteine) is needed for the production of antioxidant gluta-
thione in the brain (55). Sulfur amino acids are sensitive to
oxidative modifications by reactive oxygen-containing species.
A balance between the production of reactive oxygen-
containing species and antioxidants protects cells against in-
vaders. However, an imbalance leads to increased oxidative
stress, which is particularly damaging to cells in high demand
of oxygen such as neuronal cells (56). Increased oxidative
stress has been associated with aging and has been observed
in several disorders, including FTD (56–58).
Despite the modest sample size of the DLPFC CMC refer-
ence panel, the DLPFC contributed to significantly more
transcriptome-wide findings compared to other tissue types,
thereby highlighting the topology-specific neurodegenerative
nature of FTD. MESC analysis, an approach to examine the
genome-wide distribution of heritability, showed that the tibial
nerve had the largest proportion of heritability mediated by
local gene expression, which may reflect the comorbidity of
FTD with motor neuron disorders. However, motor neuron
disorders typically present with the degeneration of both upper
and lower motor neurons, while most (but not all) studies
indicate that sensory neurons are spared (59,60). While tibial
nerve degeneration has been observed in motor neuron dis-
orders, this nerve contains both motor and sensory axons and
Schwann cells, making it possibly less specific as tissue ofurnal
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Psychiatryinterest for motor neuron disorders (61). Therefore, current
MESC results should be validated using reference weights of
upper and lower motor neuron tissue types.
We also observed various associations outside the brain,
potentially highlighting the importance of other organ systems
in FTD. In line with this, other organ systems, such as the
gastrointestinal and musculoskeletal systems, have been
associated with FTD (62,63). On the other hand, we included
local eQTL data from many tissue types—also those that are
seemingly less disease relevant—to increase power and to
include as many genes in this exploratory study. As a result, we
might not have detected the true mechanism of disease owing
to a shared cross-tissue regulatory architecture of eQTLs be-
tween the tissue types related and nonrelated to FTD (25,64).
This is illustrated by our finding on bvFTD, for which we
identified differential regulatory gene expression only of RAB38
in tissue types outside the brain. Because RAB38 is expressed
throughout the brain (https://gtexportal.org/home/gene/RAB38)
but is not available in the brain tissue panels we used, we
hypothesize that differential expression of RAB38 in the brain
contributes to bvFTD disease risk as well. To gain a deeper
understanding of molecular mechanisms underlying FTD, future
TWAS studies should increase the sample sizes of eQTL
reference panels of disease-relevant tissue types and refine
tissue-specific information with, for instance, cell type–specific
features.
This study is a starting point for bridging the gap between
genetic variation and disease pathogenesis involving specific
genes in FTD. Nevertheless, several limitations should be
taken into account. First, where TWAS increases power over a
traditional GWAS, the small sample size of the current FTD
GWAS (n = 2154 cases, n = 4308 controls) still reduces the
power to find novel transcriptome-wide associations. As such,
future TWASs on FTD should be performed using FTD GWAS
summary statistics with a larger sample size, because this
would increase not only the power to detect true associations,
but also the robustness of results on tissue enrichment and
genetic correlations. A second major limitation is that this
study does not address the pathological heterogeneity in FTD.
The most common pathological subtypes of FTD include
abnormal aggregation of tau (frontotemporal lobar degenera-
tion [FTLD]-tau) and FTLD-TDP (65). Because we performed a
TWAS on the clinical entity of FTD, this study provides insights
only into generic mechanisms underlying FTD but not into
specific mechanisms underlying pathological subtypes. Addi-
tional studies in postmortem verified FTD cases are required to
gain more insight into distinct mechanisms underlying patho-
logical subtypes of FTD. Moreover, our results should be
replicated using independent cis eQTL datasets to exclude the
possibility that presented findings reflect false-positive find-
ings. Finally, it should be noted that TWAS or colocalization
analysis cannot be used for causal inference (64). Therefore, it
is essential that our efforts will be extended to functional
validation to further understand the relationship between FTD
and genes reported in this study.
Results presented in this study could be used as a point of
reference in future genetic association studies on FTD. We
provide evidence for the contribution of many genes, with both
tissue-shared and tissue-specific effects, to the pathogenesis
of FTD, including potential novel (i.e., SEC22B) and previouslyBiologicalreported (e.g., 17q21.31 inversion region, C4A) FTD risk loci.
Most associations were detected in DLPFC splicing data, but
tissues outside the brain may be involved in FTD as well.
However, functional validation is needed because TWASs are
sensitive to detecting associations not relevant for disease if
the disease-relevant tissue is not well represented across
reference panels. Identifying which biological processes are
genetically influenced by FTD is important for understanding
the disease etiology, and eventually for the development of
treatments.
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